Mercado de enfermedades cardiometabólicas: mapeo competitivo y perspectivas estratégicas 2031

  • Report Code : TIPRE00025374
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 293
Buy Now

Se espera que el mercado de enfermedades cardiometabólicas alcance los 121.804,49 millones de dólares en 2028 desde los 93.494,41 millones de dólares de 2021; se estima que crecerá a una tasa compuesta anual del 3,9 % durante 2021-2028.

La enfermedad cardiometabólica se caracteriza por un grupo de anomalías y síntomas que aumentan el riesgo de que las personas desarrollen enfermedad cardiovascular. La hipertensión, la obesidad, la resistencia a la insulina, la dislipidemia, el perfil deficiente del colesterol (LDL) y la tolerancia a la glucosa son algunos de los síntomas de las enfermedades cardiometabólicas. Las personas que padecen síndrome cardiometabólico son propensas a muchas otras enfermedades potencialmente mortales, como diabetes tipo 2, accidente cerebrovascular, enfermedad de las arterias coronarias (EAC) y enfermedades cardiovasculares (ECV). Tanto las condiciones genéticas como las ambientales son responsables del desarrollo de las enfermedades.

Perspectivas estratégicas

El crecimiento del mercado de enfermedades cardiometabólicas se atribuye principalmente a factores como como la creciente prevalencia de enfermedades cardiometabólicas y la innovación en la terapéutica de las CMD. Sin embargo, el subdiagnóstico de las enfermedades cardiovasculares en los países de ingresos bajos y medianos (PIBM) está obstaculizando el crecimiento del mercado.

regiones lucrativas en el mercado de enfermedades cardiometabólicas


< /h3>

Perspectivas del mercado
Creciente prevalencia de enfermedades cardiometabólicas

Las enfermedades cardiometabólicas (EMC) son una de las principales causas de muerte en todo el mundo. Estas enfermedades son causadas principalmente por un estilo de vida poco saludable, la inactividad física, el tabaquismo y una dieta poco saludable. Las CMD incluyen enfermedades cardiovasculares (ECV), diabetes mellitus e insuficiencia renal crónica. Según la OMS, alrededor de 17,9 millones de personas murieron a causa de enfermedades cardiovasculares en 2019, lo que representa el 32% de todas las muertes mundiales. De estas muertes, el 85% se debió a ataques cardíacos y accidentes cerebrovasculares.

La mayoría de las enfermedades cardiovasculares se pueden prevenir abordando los factores de riesgo conductuales, como el consumo de tabaco, las elecciones dietéticas poco saludables, la obesidad y la inactividad física. y consumo de alcohol. La diabetes es una de las enfermedades crónicas potencialmente mortales que no tiene cura funcional. Conduce a diversas complicaciones y aumenta el riesgo general de muerte prematura. Los ataques cardíacos, los accidentes cerebrovasculares, la insuficiencia renal, la amputación de piernas, la pérdida de la visión y el daño a los nervios son las principales complicaciones asociadas con la diabetes. Según la Federación Internacional de Diabetes (FID), en 2019, ~463 millones de adultos vivían con diabetes, y se espera que llegue a 700 millones en 2045.

Existe un Aumento global en el número de personas que padecen una o más CMD debido al aumento del tabaquismo, la falta de ejercicio, el consumo de alcohol y los hábitos alimentarios poco saludables. Según las estadísticas de la OMS de julio de 2021, más de 8 millones de personas mueren cada año debido al consumo de tabaco. Su consumo es mayor en los países de ingresos bajos y medios, donde el 80% de su base de consumidores mundial vive en estos países. La creciente prevalencia de la obesidad está dando lugar a que la base de pacientes también sufra TMC. Con este rápido aumento en la prevalencia de CMD, la necesidad de tratamientos adecuados para las enfermedades cardiometabólicas se ha disparado, lo que ha resultado en un enorme crecimiento del mercado.

Información basada en tipos

El mercado de enfermedades cardiometabólicas, por tipo, se segmenta en enfermedades cardiovasculares (ECV), hipertensión, diabetes tipo 2 y obesidad. El segmento de enfermedades cardiovasculares (ECV) tuvo la mayor participación del mercado en 2021 y se anticipa que el segmento registre la CAGR más alta del mercado durante el período de pronóstico.

Mercado de enfermedades cardiometabólicas, por tipo: 2021 y 2028


Información basada en el tratamiento

Por tratamiento, el mercado de enfermedades cardiometabólicas se segmenta en inhibidores de la ECA, diuréticos, Glucophage y otros. El segmento de inhibidores de la ECA tuvo la mayor participación del mercado en 2021, y se prevé que el mismo segmento registre la CAGR más alta del mercado durante el período de pronóstico.

Información basada en dosis

El mercado de enfermedades cardiometabólicas, por dosis, se divide en tabletas e inyecciones. El segmento de tabletas tuvo una mayor participación de mercado en 2021 y se prevé que registre una CAGR más alta en el mercado durante el período de pronóstico.

Ruta de conocimientos basados en la administración

El mercado de enfermedades cardiometabólicas, según la vía de administración, se bifurca en oral e intravenosa. En 2021, el segmento oral tuvo una mayor participación de mercado y se espera que registre una CAGR más alta en los próximos años.

Información basada en los usuarios finales

El mercado de enfermedades cardiometabólicas, por usuarios finales, se segmenta en entornos clínicos, hospitalarios y de atención domiciliaria. En 2021, el segmento hospitalario tuvo la mayor participación del mercado y se prevé que registre la CAGR más alta del mercado durante el período de pronóstico.


Los lanzamientos y aprobaciones de productos son estrategias comúnmente adoptadas por las empresas para ampliar su huella global y sus carteras de productos. Además, los actores del mercado de pruebas desarrolladas por el laboratorio se centran en la estrategia de asociación para ampliar su clientela, lo que, a su vez, les permite mantener su marca a nivel mundial.

El informe segmenta el mercado de enfermedades cardiometabólicas de la siguiente manera

Según el tipo, el mercado de enfermedades cardiometabólicas se segmenta en enfermedades cardiovasculares (ECV), hipertensión, diabetes tipo 2 y obesidad. Según el tratamiento, el mercado se segmenta en inhibidores de la ECA, diuréticos, glucófagos y otros. Según la dosis, el mercado de enfermedades cardiometabólicas se divide en tabletas e inyecciones. Según la vía de administración, el mercado se divide en oral e intravenoso. Según los usuarios finales, el mercado de enfermedades cardiometabólicas se segmenta en entornos clínicos, hospitalarios y de atención domiciliaria. Por geografía, el mercado está segmentado en América del Norte (EE.UU., Canadá y México), Europa (Reino Unido, Alemania, Francia, Italia, España y el resto de Europa), Asia Pacífico (China, Japón, India, Australia). , Corea del Sur y el resto de Asia Pacífico), Medio Oriente y África (EAU, Arabia Saudita, Sudáfrica y el resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina y el resto de Asia Pacífico). Resto de América del Sur y Central).

Perfiles de empresas

  • Eli Lilly and Company< /li>
  • Bayer AG
  • Arrowhead Pharmaceuticals, Inc
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/ S
  • AstraZeneca
  • Alnylam Pharmaceuticals, Inc.
  • Cardax, Inc
  • Kowa Company, Ltd.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is cardiometabolic diseases market?

Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.

What are the driving factors for the cardiometabolic diseases market across the country?

The factors that are driving and restraining factors that will affect cardiometabolic diseases market in the coming years. Factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.

Who are the major players in the cardiometabolic diseases market?

The cardiometabolic diseases market majorly consists of the players such as as Eli Lilly and Company; Bayer AG; Arrowhead Pharmaceuticals, Inc; Novartis AG; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Cardax, Inc.; and Kowa Company, Ltd among others.

Which segment is dominating the cardiometabolic diseases market?

The global cardiometabolic diseases market cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period.

The List of Companies - Cardiometabolic Diseases Market

  1. Eli Lilly and Company
  2. Bayer AG
  3. Arrowhead Pharmaceuticals, Inc
  4. Novartis AG
  5. Boehringer Ingelheim International GmbH
  6. Novo Nordisk A/S
  7. AstraZeneca
  8. Alnylam Pharmaceuticals, Inc.
  9. Cardax, Inc
  10. Kowa Company, Ltd.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports